SCNI News and Press, Scanner Technologies Corp From 10/31/23

JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoi...

2023-10-30 17:28:10 ET More on Scinai Immunotherapeutics Ltd. Seeking Alpha’s Quant Rating on Scinai Immunotherapeutics Ltd. Historical earnings data for Scinai Immunotherapeutics Ltd. Financial information for Scinai Immunotherapeutics Ltd. For furthe...

Researchers from the University of Southampton, United Kingdom and La Jolla Institute for Immunology (LJI) have identified a group of immune cells that may be responsible for severe asthma. Identified as   cytotoxic CD4+ tissue-resident memory T cells , these cells congregate in the lungs ...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, will be atte...

Showcasing Scinai’s end-to-end cGMP Biologics CDMO services at booth 271 Pursuing partnerships for Scinai’s pipeline of novel VHH antibody-based therapies JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today an...

Scinai will exhibit at the upcoming CPHI Barcelona event, showcasing its CDMO services The company expanded into the CDMO business earlier this year, operating under the banner Scinai Bioservices Scinai’s boutique end-to-end CDMO business division serves pharmaceutical, biotech, and al...

Proper and early treatment is crucial to preventing worse patient outcomes and limiting community transmission when infectious diseases such as influenza, measles, hepatitis A, B, and C, and the novel coronavirus are involved. However, infectious-disease treatment can become less effective due to...

Scinai announced positive results suggesting the therapeutic potential of its anti-IL-17 VHH antibodies (NanoAbs) in treating plaque psoriasis The preclinical study showed that the introduction of the NanoAbs downregulated the standard molecular markers S100A7, CXCL1, and CCL20, that are often ...

New research from the VA Portland Health Care System and Oregon Health & Sciences University has identified a biomarker that can potentially improve autoimmune disease treatment outcomes. The research team investigated ankylosing spondylitis (AS), an inflammatory disease that causes verte...

The coronavirus pandemic put a spotlight on the potential danger of infectious diseases and has helped spur research to develop faster and more efficient means of diagnosing infectious diseases. Early diagnosis of infectious diseases is critical to developing proper treatment and prevention pro...